Leaptx
1 known investors
Leap Therapeutics (Nasdaq: LPTX) develops targeted and immuno-oncology antibody therapeutics for cancer patients, with its lead candidate DKN-01 (sirexatamab), an anti-DKK1 monoclonal antibody, in clinical development for esophagogastric, gynecologic, and colorectal cancers. Its pipeline also includes FL-301, a Claudin18.2-targeting antibody for gastric and pancreatic cancer, and FL-501, a GDF-15-targeting antibody in preclinical development.
Investors Β· 1
Frequently asked questions
- What does Leaptx do?
- Leap Therapeutics (Nasdaq: LPTX) develops targeted and immuno-oncology antibody therapeutics for cancer patients, with its lead candidate DKN-01 (sirexatamab), an anti-DKK1 monoclonal antibody, in clinical development for esophagogastric, gynecologic, and colorectal cancers. Its pipeline also includes FL-301, a Claudin18.2-targeting antibody for gastric and pancreatic cancer, and FL-501, a GDF-15-targeting antibody in preclinical development.
- Who are Leaptx's investors?
- Leaptx's investors include Torrey Pines Investment.